Humanized Anti-IL2 Antibody KAPKA Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody inhibitors of IL2 activity lack specificity, leading to undesirable side effects due to their limited target specificity and mode of action, which often involves competing with the IL2 receptor for binding, requiring higher doses and longer times to achieve therapeutic effects.
Innovation Solution
A humanized monoclonal antibody specifically binding to human IL2, comprising a light chain variable region with the amino acid sequence KAPKA at positions 42-46, which neutralizes IL2 activity by binding to IL2 prior to, during, or subsequent to its interaction with the IL2 receptor, without competing for the receptor binding site, allowing for lower therapeutic concentrations and faster action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known antibody inhibitors bind to the IL2 receptor to inhibit IL2 activity, then IL2 activity is inhibited, but the antibodies require higher doses and longer times to achieve therapeutic effects due to competition for the receptor binding site
Solution Approach 1:
The patent extracts the binding function from the IL2 receptor and relocates it to the antibody itself. The anti-IL2 antibody contains a binding domain that directly binds IL2 with high affinity, eliminating the need to compete for the receptor binding site. This extraction of the binding function from the receptor and placement in the antibody resolves the contradiction by allowing effective IL2 inhibition at lower doses without receptor competition.
Solution Approach 2:
The patent introduces an intermediary binding domain within the antibody structure that mediates the interaction between the antibody and IL2. This intermediary binding domain, derived from the IL2 receptor sequence but integrated into the antibody, allows the antibody to bind IL2 directly without competing for the native receptor site, thereby reducing the required antibody dose while maintaining effective IL2 inhibition.
2Reliability
If known antibody inhibitors compete with the IL2 receptor for binding, then IL2 activity is inhibited, but side effects increase due to limited target specificity
Solution Approach 1:
The patent applies local quality by creating a highly specific binding interface within the antibody's binding domain that matches the IL2 molecular structure precisely. The binding domain contains specific amino acid sequences (including the KAPKA motif) that are locally optimized to recognize and bind only IL2 with high affinity and specificity, minimizing off-target effects while maintaining reliable IL2 inhibition.
Solution Approach 2:
The patent changes the binding parameters by modifying the antibody's binding domain to have optimized affinity and specificity for IL2. The binding domain incorporates specific sequence variations (such as the KAPKA motif at positions 42-46) that tune the binding characteristics to preferentially recognize IL2 over other cytokines, thereby reducing side effects while maintaining effective IL2 activity inhibition.
3Speed
If the antibody binds to IL2 prior to receptor interaction, then therapeutic effects are achieved faster, but the antibody must maintain stability and specificity throughout multiple binding states
Solution Approach 1:
The patent applies dynamics by designing the antibody binding domain to adaptively interact with IL2 in multiple binding states. The binding domain can accommodate IL2 whether it is free in solution or already bound to the receptor, allowing the antibody to neutralize IL2 activity rapidly across different temporal states. This dynamic binding capability accelerates therapeutic action while maintaining complex stability through flexible molecular recognition.
Data Source
AI summary
The invention relates to a humanized monoclonal antibody or fragment thereof which specifically binds to human interlukin-2 (IL2), whereby said humanized monoclonal antibody neutralizes the activity of human IL2 by binding to the human IL2 prior to, during, and/or subsequent to the binding of the human IL2 to the human IL2-receptor, and wherein the light chain variable region of the humanized monoclonal antibody comprises in its second framework region the contiguous amino acid sequence KAPKA at amino acid positions 42-46.